We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-13%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$46B
AUM Growth
-$5.82B
Cap. Flow
+$1.91B
Cap. Flow %
4.16%
Top 10 Hldgs %
16.37%
Holding
3,033
New
111
Increased
2,420
Reduced
427
Closed
53

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$127M
2
CI icon
Cigna
CI
+$54M
3
CVS icon
CVS Health
CVS
+$38.8M
4
MPC icon
Marathon Petroleum
MPC
+$28.9M
5
FANG icon
Diamondback Energy
FANG
+$19M

Sector Composition

Rank Sector Weight
1 Technology 16.95%
2 Financials 15.85%
3 Healthcare 14.41%
4 Consumer Discretionary 10.13%
5 Industrials 10.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IBRX icon
2951
ImmunityBio
IBRX
$7.68B
$44K ﹤0.01%
38,242
+9,570
+33% +$21.9K
AMPE
2952
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$44K ﹤0.01%
373
+132
+55% +$20.3K
EPE
2953
DELISTED
EP Energy Corporation
EPE
$44K ﹤0.01%
62,447
+16,730
+37% +$25K
NL icon
2954
NLI Holdings
NL
$281M
$42K ﹤0.01%
+11,970
New +$58.4K
CLSD
2955
DELISTED
Clearside Biomedical
CLSD
$40K ﹤0.01%
2,465
+805
+48% +$37.8K
OVID icon
2956
Ovid Therapeutics
OVID
$489M
$40K ﹤0.01%
16,551
+5,310
+47% +$24.2K
PFIE
2957
DELISTED
Profire Energy, Inc
PFIE
$40K ﹤0.01%
27,755
+9,660
+53% +$22.5K
FBIO icon
2958
Fortress Biotech
FBIO
$92.7M
$39K ﹤0.01%
3,009
+944
+46% +$15.8K
SER icon
2959
Serina Therapeutics
SER
$33.4M
$38K ﹤0.01%
+364
New +$46.3K
MARK
2960
DELISTED
Remark Holdings, Inc.
MARK
$38K ﹤0.01%
3,166
+1,041
+49% +$22.7K
PIR
2961
DELISTED
Pier 1 Imports, Inc.
PIR
$37K ﹤0.01%
5,970
+1,583
+36% +$43.3K
SGYP
2962
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$36K ﹤0.01%
318,791
+97,448
+44% +$63.9K
MLNT
2963
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$35K ﹤0.01%
8,826
+3,280
+59% +$41.9K
KEG
2964
DELISTED
Key Energy Services, Inc. Common Stock
KEG
$31K ﹤0.01%
14,798
+4,150
+39% +$30.3K
UMC icon
2965
United Microelectronic
UMC
$48.4B
$30K ﹤0.01%
16,910
PHIIK
2966
DELISTED
PHI, Inc. Non-Voting Common Stock
PHIIK
$29K ﹤0.01%
15,531
+4,070
+36% +$23.6K
ZN
2967
DELISTED
Zion Oil & Gas, Inc.
ZN
$28K ﹤0.01%
66,482
+22,080
+50% +$19.1K
SN
2968
DELISTED
Sanchez Energy Corporation
SN
$27K ﹤0.01%
99,200
+32,683
+49% +$41.9K
AAC
2969
DELISTED
AAC Holdings
AAC
$24K ﹤0.01%
17,056
+4,540
+36% +$18.2K
TRQ
2970
DELISTED
Turquoise Hill Resources Ltd
TRQ
$21K ﹤0.01%
1,250
BW icon
2971
Babcock & Wilcox
BW
$1.42B
$20K ﹤0.01%
5,155
+1,299
+34% +$11.6K
NH
2972
DELISTED
NantHealth, Inc
NH
$15K ﹤0.01%
1,825
+549
+43% +$9.62K
BLRX
2973
BioLineRX
BLRX
$11.8M
$8K ﹤0.01%
31
IMUX icon
2974
Immunic
IMUX
$191M
$7K ﹤0.01%
94
+30
+47% +$3.51K
LFWD icon
2975
ReWalk Robotics
LFWD
$20.4M
$2K ﹤0.01%
+5
New +$5.3K

Similar funds

RhumbLine Advisers's Q4 2018 Portfolio in Review

As of Q4 2018, RhumbLine Advisers held 3,033 positions worth $46B, down 11% from $51.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

RhumbLine Advisers deployed $1.91B of net new capital in Q4 2018, opening 111 new positions and adding to 2,420 existing holdings. Its largest new stake was Linde: 805,738 shares worth $126M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Apple, an estimated $30.2M trimmed.

  • RhumbLine Advisers's largest Q4 2018 buy was Linde: 805,738 shares worth $126M.
  • RhumbLine Advisers added most to Cigna in Q4 2018, an estimated $54M increase.
  • RhumbLine Advisers's biggest Q4 2018 reduction was Apple, cutting an estimated $30.2M.
  • RhumbLine Advisers fully exited Aetna Inc in Q4 2018, selling an estimated $124M.
  • RhumbLine Advisers's ten largest holdings make up 16% of its $46B portfolio in Q4 2018.
  • RhumbLine Advisers opened 111 new positions and closed 53 in Q4 2018.
  • RhumbLine Advisers's portfolio value fell 11% quarter-over-quarter to $46B.

Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.